Takeda Pharmaceutical Co ADR (NYSE:TAK) price on Friday, February 28, rose 0.49% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $14.41.
A look at the stock’s price movement, the close in the last trading session was $14.34. The PE ratio in trailing twelve months stood at 33.89. Turning to its 52-week performance, $15.08 and $12.57 were the 52-week high and 52-week low respectively. Overall, TAK moved 8.26% over the past month.
Takeda Pharmaceutical Co ADR’s market cap currently stands at around $45.69 billion, with investors looking forward to this quarter’s earnings report slated for in April. The company has a Forward Dividend ratio of 0.62, with its dividend yield at 4.29%. As such, investors might be keen on an upside in the stock’s price ahead of the scheduled earnings report.
Analysts have a consensus estimate of 1.1T for the company’s revenue for the quarter, with a low and high estimate of 1.06T and 1.16T respectively. The average forecast suggests up to a 4.39% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 4.62T, representing a 676.23% jump on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that TAK is a 100% Buy. On the other hand, the stock is on average a 50% Sell as suggested by medium term indicators while long term indicators are putting the stock in 50% Buy category.
3 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 1 analyst(s) rate the stock as a Hold, 2 recommend TAK as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
The technical evaluation for the stock shows the PEG ratio is 1.24, with TAK’s current price about 4.86% and 7.55% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 69.56, while 7-day volatility ratio is 0.80% and 0.99% in the 30-day chart. Further, Takeda Pharmaceutical Co ADR (TAK) has a beta value of 0.49, and an average true range (ATR) of 0.19.
If we refocus on Takeda Pharmaceutical Co ADR (NYSE:TAK), historical trading data shows that trading volumes averaged 1.72 million over the past 3 months. The company’s latest data on shares outstanding shows there are 3.17 billion shares.
The 0.02% of Takeda Pharmaceutical Co ADR’s shares are in the hands of company insiders while institutional holders own 5.04% of the company’s shares. Current price change has pushed the stock 8.84% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the TAK stock continues to rise going into the next quarter.
